Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Index- P/E- EPS (ttm)-1.05 Insider Own0.60% Shs Outstand103.45M Perf Week5.83%
Market Cap356.90M Forward P/E- EPS next Y-1.23 Insider Trans-19.04% Shs Float102.64M Perf Month-17.07%
Income-106.90M PEG- EPS next Q-0.23 Inst Own73.50% Short Float36.26% Perf Quarter-27.37%
Sales130.00M P/S2.75 EPS this Y-21.80% Inst Trans-0.08% Short Ratio17.18 Perf Half Y-34.91%
Book/sh1.15 P/B3.00 EPS next Y-23.00% ROA-25.50% Target Price6.00 Perf Year-64.76%
Cash/sh3.13 P/C1.10 EPS next 5Y4.70% ROE-75.30% 52W Range3.13 - 10.29 Perf YTD-62.00%
Dividend- P/FCF- EPS past 5Y-65.30% ROI-42.20% 52W High-66.47% Beta1.18
Dividend %- Quick Ratio6.60 Sales past 5Y-0.60% Gross Margin84.20% 52W Low10.22% ATR0.25
Employees98 Current Ratio7.50 Sales Q/Q298.20% Oper. Margin-33.80% RSI (14)42.09 Volatility7.23% 5.91%
OptionableYes Debt/Eq1.85 EPS Q/Q54.50% Profit Margin-82.20% Rel Volume0.44 Prev Close3.36
ShortableYes LT Debt/Eq1.82 EarningsNov 03 AMC Payout- Avg Volume2.17M Price3.45
Recom3.60 SMA20-6.91% SMA50-13.67% SMA200-36.04% Volume968,000 Change2.68%
25-Feb-14Reiterated WallachBeth Hold $11 → $8
15-Nov-13Initiated WallachBeth Hold $11
03-Oct-13Upgrade Cowen Hold → Outperform $19
19-Jul-13Downgrade Needham Buy → Hold
18-Jan-13Reiterated MLV & Co Buy $40 → $21
24-Sep-12Reiterated Needham Buy $38 → $32
19-Jul-12Reiterated MLV & Co Buy $34 → $40
18-Jul-12Reiterated Rodman & Renshaw Mkt Outperform $39 → $52
18-Jul-12Downgrade Brean Murray Buy → Hold
30-Apr-12Reiterated MLV & Co Buy $30 → $34
23-Feb-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $39
23-Feb-12Upgrade Brean Murray Sell → Hold $2
23-Feb-12Reiterated MLV & Co Buy $22 → $30
23-Feb-12Reiterated JMP Securities Mkt Outperform $16 → $45
17-Jan-12Reiterated MLV & Co Buy $16 → $22
05-Jan-12Initiated Rodman & Renshaw Mkt Perform
29-Oct-10Reiterated JMP Securities Mkt Outperform $12 → $16
03-Aug-10Downgrade Brean Murray Hold → Sell $2
16-Jul-10Reiterated Wedbush Outperform $20 → $10
16-Jul-10Reiterated JMP Securities Mkt Outperform $18 → $12
20-Oct-14 01:10PM  Notable option trades in equities optionMONSTER
09-Oct-14 07:00PM  Endo Buyout Of Auxilium Joins Two Changing Firms at Investor's Business Daily
08-Oct-14 04:50PM  Emergent BioSolutions Revamps Business to Drive Earnings Zacks
07-Oct-14 04:40PM  Halozyme's PEGPH20 Receives FDA Orphan Drug Designation Zacks -5.67%
06-Oct-14 07:00AM  Newly Published Data Highlight the Effects of Weight Loss With Qsymia in Type 2 Diabetes Marketwired
02-Oct-14 12:10PM  Zafgen Aims Obesity Drug At Rare, Deadly Disease at Forbes
30-Sep-14 10:37AM  [video] Zafgen CEO: 2015 Will Be Data Rich Year for Obesity Treatment at TheStreet
19-Sep-14 05:25PM  VIVUS and Auxilium Announce Stendra Label Expansion Zacks
08:14AM  VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session Zacks
18-Sep-14 05:25PM  Rite Aid and Pier 1 are big market movers AP +12.37%
03:45PM  UPDATE 1-Vivus' Stendra gets FDA approval for use 15 minutes before sex Reuters
12:34PM  Pier 1 punished, Vivus lifting off, Amazon unveils new Kindles Yahoo Finance
12:21PM  FDA OKs faster-acting label for ED drug Stendra AP
12:09PM  VIVUS, Inc.s Stendra lets you get it up faster Yahoo Finance Blogs
11:00AM  [$$] Stendra Gets FDA Approval as 'On-Demand' Drug at The Wall Street Journal
10:17AM  Why VIVUS (VVUS) Stock Is Up Today at TheStreet
09:55AM  Vivus, Inc. Opens Sharply Higher On ED Drug Marketing Approval Benzinga
08:31AM  Pharmalot, Pharmalittle: We're Reading About Vivus, Gilead and Lots More!! at The Wall Street Journal
07:37AM  Faster-acting erectile dysfunction drug gets FDA approval Reuters
06:05AM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
06:00AM  VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity PR Newswire
06:00AM  VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity Marketwired
16-Sep-14 04:05PM  VIVUS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
09:48AM  Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy at TheStreet
11-Sep-14 05:15PM  [video] Orexigen drops in spite of FDA approval at CNBC
04:10PM  How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval? at TheStreet
04:00PM  U.S. FDA panel: Novo Nordisk's liraglutide safe/effective for obesity Reuters
01:23PM  Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised at TheStreet
12:50PM  [$$] FDA Approves Weight-Loss Drug at The Wall Street Journal
07:18AM  FDA approves weight-loss drug Contrave AP
10-Sep-14 09:16PM  New Drug to Treat Obesity Gains Approval by F.D.A. at New York Times
07:58PM  FDA Approves Contrave Weight Loss Drug From Orexigen And Takeda at Forbes
07:00PM  Orexigen Wins U.S. FDA Approval for Weight-Loss Pill at Bloomberg
09-Sep-14 09:32AM  FDA staff: Novo Nordisk drug liraglutide effective for obesity Reuters
28-Aug-14 04:06PM  VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
26-Aug-14 04:00PM  VIVUS Acquires Certain Topamax Related Patents from J&J Zacks
06:45AM  Traders look for rebound in Vivus optionMONSTER
25-Aug-14 08:37AM  Vivus acquires patent rights to Qsymia ingredient AP
07:05AM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:00AM  VIVUS Announces Acquisition of Topiramate-Related Patents From Janssen Pharmaceuticals Marketwired
19-Aug-14 10:45AM  You've got obesity all wrong: Zafgen CEO at CNBC
18-Aug-14 06:26AM  [video] Obesity treatment sales fall short at CNBC
15-Aug-14 04:05PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
01:04PM  VIVUS INC Financials EDGAR Online Financials
12-Aug-14 04:10PM  VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
01:58PM  Auxilium Posts Wider-than-Expected Loss, Outlook Maintained Zacks
08-Aug-14 10:00AM  VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales Zacks
07-Aug-14 04:30PM  Vivus Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:10PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:05PM  VIVUS Reports Second Quarter 2014 Financial Results Marketwired
07:07AM  Q2 2014 Vivus Inc. Earnings Release - After Market Close CCBN
06-Aug-14 05:00PM  Will Emergent BioSolutions (EBS) Earnings Disappoint in Q2? Zacks
04:10PM  Will Mylan (MYL) Earnings in Q2 Disappoint Expectations? Zacks
04-Aug-14 10:10AM  Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss Zacks
31-Jul-14 07:00AM  VIVUS Announces Date of Second Quarter 2014 Update and Financial Results Conference Call GlobeNewswire -5.68%
19-Jul-14 04:14PM  The Implications of Obesity as a Disability in Europe at Motley Fool
15-Jul-14 06:49PM  Lightning Round: Akamai, GE & more at CNBC
11-Jul-14 05:02PM  3 Crashing Biotechs: Is 1 a Buy? at Motley Fool
03:45PM  Arena Pharmaceuticals-Eisai Boost Obesity Drug Sales Force Zacks
03-Jul-14 04:11PM  3 Stocks Even Volatility-Loving Nasdaq Investors Hate at Motley Fool
27-Jun-14 05:30PM  Are Investors Wrong About Orexigen Therapeutics?
12:37PM  Arena's Belviq Sales Flat Again at Seeking Alpha
25-Jun-14 05:30PM  Are Investors Wrong About VIVUS? at Motley Fool
24-Jun-14 06:20AM  How Bad Is This Delay for Orexigen Therapeutics, Inc? at Motley Fool
23-Jun-14 12:01AM  Early Results Arrive on Weight-Loss Pills That Expand in the Stomach at New York Times
20-Jun-14 11:34AM  The Anti-Obesity Space Is Not As Simple As Some Think at Seeking Alpha
03:19AM  Now Available: Shares in Zafgen, the Best Obesity Drugmaker to Date at Motley Fool
19-Jun-14 03:12PM  Why Zafgen Inc. Shares Roared Higher at Motley Fool
17-Jun-14 05:05PM  VIVUS INC Files SEC form 8-K/A, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
07:05AM  VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
16-Jun-14 04:19PM  What Will It Take For Arena Stock To Rise? at Seeking Alpha
13-Jun-14 04:05PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
02:56PM  Vivus Suit Preserves Exclusivity Of Qsymia - For Now at Seeking Alpha
01:22PM  5 Stocks Poised for Breakouts at TheStreet
12-Jun-14 04:50PM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
04:32PM  VIVUS Files Lawsuit Against Actavis for Infringement of Qsymia Patents Marketwired
08:00AM  EnteroMedics: A Preview of the Weight-Loss Zapper FDA Panel at TheStreet
07:00AM  VIVUS to Present at Upcoming Investor Conference Marketwired
11-Jun-14 05:07PM  Why Orexigen Therapeutics Inc. Shares Were Throttled at Motley Fool
05:02PM  Orexigen Irony: No VIVUS Bounce at 24/7 Wall St.
02:11PM  Why Orexigen Therapeutics is Falling Today at Motley Fool
12:02PM  Why Don't Doctors Prescribe More Weight-Loss Drugs? at BusinessWeek
11:55AM  Orexigen Obesity Drug Decision Delayed By FDA at Investor's Business Daily
11:34AM  Down 18%: Is Orexigen a Bad News Buy? at Motley Fool
10:07AM  Orexigen shares hit by FDA delay in obesity drug at CNBC
09:37AM  Top Swing Trade Ideas for Wednesday June 11: Facebook, Vivus, More at TheStreet
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia, a drug for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II clinical studies for the treatment of obstructive sleep apnea and diabetes. The company has an agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fischer Seth H.Z.Chief Executive OfficerMar 11Buy6.073,08018,6953,080Mar 12 06:37 PM
DENNER ALEXANDER JDirectorNov 11Buy8.78149,7761,315,0332,573,943Nov 12 05:08 PM
DENNER ALEXANDER JDirectorNov 08Buy8.52417,0683,553,4192,424,167Nov 12 05:08 PM